SCHEMBL6490617

SCHEMBL6490617

Cc1cc(-c2ccc(C(=O)O)cc2)cc2c1nc(C)n2Cc1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
TRPM8 Q7Z2W7 10/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
GLA P06280 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
AGBL2 Q5U5Z8 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488927 0.91 MRGPRX4 (0.44) DCTPP1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL6498752 0.90 MEN1 (0.41) DCTPP1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL6488962 0.88 MRGPRX4 (0.41) DCTPP1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL6502236 0.84 MRGPRX4 (0.39) CYP1A2CYP3A4CYP2D6CYP2C19GLA
SCHEMBL7195728 0.84 CYP1A2 (0.38) CYP1A2CYP3A4CYP2D6CYP2C19GLA
SCHEMBL7199966 0.84 CYP1A2 (0.38) CYP1A2CYP3A4CYP2D6CYP2C19GLA
SCHEMBL7200308 0.82 CYP3A4 (0.37) CYP1A2CYP3A4CYP2D6CYP2C19GLA
SCHEMBL6489988 0.81 DCTPP1 (0.40) DCTPP1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL6490408 0.80 JMJD6 (0.41) CYP1A2CYP3A4CYP2D6CYP2C19HPGD
SCHEMBL6488333 0.80 MRGPRX4 (0.43) DCTPP1CYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD DCTPP1 1534/4885CYP1A2 247/4885CYP3A4 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.